Description
Chlorisondamine is an antagonist of nicotinic acetylcholine receptors (nAChRs; IC
50 = 1.8 μM in rat striatal synaptosomes) and a ganglion blocker. It decreases dopamine release induced by nicotine (Item Nos.
16535 |
20887) in a dose-dependent manner in rat striatal synaptosomes at concentrations ranging from 0-100 μM. The effect of chlorisondamine is long-lasting, with a 10 mg/kg dose blocking nicotine-induced stimulant activity for at least five weeks. Chlorisondamine (5 μg, i.c.v.) prevents rats from acquiring a (–)-nicotine-induced conditioned taste aversion response, a model of the aversive effects of nicotine. It also inhibits autonomic ganglia, providing approximately 50% inhibition of the contractile response in feline superior cervical ganglion nictitating membrane preparations when administered at a dose of 50 mg/kg.
References
[1] H. EL-BIZRI P. B S C. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro[J]. British Journal of Pharmacology, 1994, 111 2: 406-413. DOI:
10.1111/j.1476-5381.1994.tb14749.x[2] CLARKE P B. Chronic central nicotinic blockade after a single administration of the bisquaternary ganglion-blocking drug chlorisondamine.[J]. British Journal of Pharmacology, 1984, 83 2: 527-535. DOI:
10.1111/j.1476-5381.1984.tb16517.x[3] C. REAVILL. Chlorisondamine blocks acquisition of the conditioned taste aversion produced by ()-nicotine[J]. Neuropharmacology, 1986, 25 9: Pages 1067-1069. DOI:
10.1016/0028-3908(86)90204-2[4] A J PLUMMER. Ganglionic blockade by a new bisquaternary series, including chlorisondamine dimethochloride.[J]. Journal of Pharmacology and Experimental Therapeutics, 1955, 115 2: 172-184.
